We are live on ! Find out more
APUS

Apimeds Pharmaceuticals US

8 hedge funds and large institutions have $712K invested in Apimeds Pharmaceuticals US in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

45% more capital invested

Capital invested by funds: $490K → $712K (+$222K)

33% more funds holding

Funds holding: 68 (+2)

0.08% more ownership

Funds ownership: 0.24%0.32% (+0.08%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
Reduced
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HTHT
1
Hemenway Trust Hemenway Trust
New Hampshire
$445K +$463K +25,000 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$105K +$109K +5,899 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$54.7K +$57K +3,075 New
Renaissance Technologies
4
Renaissance Technologies
New York
$49.6K +$51.7K +2,789 New
XT
5
XTX Topco
Cayman Islands
$33.3K +$34.7K +1,874 New
HF
6
HRT Financial
New York
$24K +$25.1K +1,357 New
Bank of America
7
Bank of America
North Carolina
$52
JP Morgan Chase
8
JP Morgan Chase
New York
$14
YAG
9
Yorkville Advisors Global
New Jersey
-$440K -25,000 Closed
Citadel Advisors
10
Citadel Advisors
Florida
-$23.5K -1,336 Closed
Goldman Sachs
11
Goldman Sachs
New York
-$21.1K -1,199 Closed
TRCT
12
Tower Research Capital (TRC)
New York
-$5.55K -315 Closed